FMA
ESPR

FNY Managed Accounts’s Esperion Therapeutics ESPR Stock Holding History

FNY Managed Accounts’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-5
Closed -$462 – 115
2016
Q3 		$462 Buy
+5
New +$57 ﹤0.01% 408

Other funds holding ESPR

PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FNY Managed Accounts's ESPR Position: Q2 2017 in Review

FNY Managed Accounts sold out of Esperion Therapeutics (ESPR) in Q2 2017, closing a stake of 265 shares — an estimated $9K sold.

FNY Managed Accounts first reported a position in ESPR in Q2 2016 and held it in 3 quarters. The position peaked at $1.98M in Q2 2016. 131 funds tracked by Wall St. Rank hold ESPR as of Q2 2017.

  • FNY Managed Accounts reported no remaining Esperion Therapeutics position as of Q2 2017 after selling out during the quarter.
  • FNY Managed Accounts sold 265 Esperion Therapeutics shares in Q2 2017, an estimated $9K.
  • FNY Managed Accounts first reported a position in Esperion Therapeutics in Q2 2016 and held it in 3 quarters.
  • FNY Managed Accounts's Esperion Therapeutics position peaked at $1.98M in Q2 2016.
  • 131 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2017.

Based on FNY Managed Accounts's 13F filing for Q2 2017, filed 10 Aug 2017.